Altre lingue SanBio Company Limited OTC Markets

Azioni

SNBOY

US7995731004

Tempo differito OTC Markets Altri mercati azionari 20:09:17 09/04/2024			Variaz. 5gg	Var. 1 gen.
2,81 ^USD	-48,72%		-.--%	-.--%

17/06	Le perdite attribuibili di SanBio si riducono nei tre mesi fiscali	MT
12/06	SanBio Company Limited annuncia un aggiornamento sullo stato di approvazione della produzione e della commercializzazione del programma Sb623 per la lesione cerebrale traumatica cronica in Giappone	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

SanBio Awaits Official Approval for Brain Injury Treatment Candidate After Positive Deliberation by Regulatory Subcommittee	05:23
SanBio’s Attributable Losses Narrows in Fiscal Three Months	17/06
Approval Pending for SanBio's Brain Injury Treatment Candidate as Deliberations Continue	13/06
SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan	12/06
SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March	19/03
SanBio Books Non-operating Income, Extraordinary Gains, Deferred Income Taxes in Fiscal 2024	19/03
SanBio's FY2024 Attributable Net Loss Narrows on Lower Costs, Forex Gains	19/03
Sanbio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fiscal Year Ending January 31, 2025, and Full Fiscal Year Ending January 31, 2025	18/03
SanBio Liquidates Singapore Unit	14/02
Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan	25/01
SanBio to Cancel Certain Stock Options	10/01
SanBio Logs Extraordinary Gain from Asset Sale of US Unit	21/12
Sanbio Widens Nine-Month Attributable Net Loss	15/12
Sanbio Cuts Staff Amid Restructuring of Overseas Subsidiary	15/12
Sanbio Expects to Receive Regulatory Nod for Stem Cell Therapy Candidate in March 2024	15/12
SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	14/12
SanBio's Overseas Subsidiary to Carry Out Personnel Reduction by November	12/07/23
SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	14/06/23
SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2024	14/06/23
Japan Stock Market Remains Jittery Despite Damage Control; Toyota Industries Plummets 11% Over Fresh Data Scandal	20/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue SanBio Company Limited OTC Markets

Azioni

SNBOY

US7995731004

Altre lingue

Filtri